

# James B Dale

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2327756/publications.pdf>

Version: 2024-02-01

126  
papers

7,444  
citations

47006

47  
h-index

62596

80  
g-index

130  
all docs

130  
docs citations

130  
times ranked

3230  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers. <i>Clinical Infectious Diseases</i> , 2005, 41, 1114-1122.	5.8	271
2	Blocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection. <i>Cell</i> , 2018, 173, 1083-1097.e22.	28.9	265
3	A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine Development. <i>Journal of Infectious Diseases</i> , 2014, 210, 1325-1338.	4.0	257
4	Epitopes of streptococcal M proteins shared with cardiac myosin.. <i>Journal of Experimental Medicine</i> , 1985, 162, 583-591.	8.5	222
5	Immunogenicity of a 26-Valent Group A Streptococcal Vaccine. <i>Infection and Immunity</i> , 2002, 70, 2171-2177.	2.2	221
6	New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. <i>Vaccine</i> , 2011, 29, 8175-8178.	3.8	219
7	Type-specific protective immunity evoked by synthetic peptide of Streptococcus pyogenes M protein. <i>Nature</i> , 1981, 292, 457-459.	27.8	194
8	Prevalence of Rheumatic Heart Disease in Children and Young Adults in Nicaragua. <i>American Journal of Cardiology</i> , 2010, 105, 1809-1814.	1.6	165
9	Multiple, heart-cross-reactive epitopes of streptococcal M proteins.. <i>Journal of Experimental Medicine</i> , 1985, 161, 113-122.	8.5	161
10	Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. <i>Infection and Immunity</i> , 1996, 64, 1495-1501.	2.2	159
11	Cloning, sequencing, and expression of a fibronectin/fibrinogen-binding protein from group A streptococci. <i>Infection and Immunity</i> , 1994, 62, 3937-3946.	2.2	152
12	Streptococcal C5a peptidase is a highly specific endopeptidase. <i>Infection and Immunity</i> , 1992, 60, 5219-5223.	2.2	151
13	Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci. <i>Annals of Medicine</i> , 2002, 34, 77-87.	3.8	150
14	Safety and Immunogenicity of a Recombinant Multivalent Group A Streptococcal Vaccine in Healthy Adults. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 709.	7.4	144
15	Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. <i>Journal of Immunology</i> , 1993, 151, 2820-8.	0.8	133
16	Protective antigenic determinant of streptococcal M protein shared with sarcolemmal membrane protein of human heart.. <i>Journal of Experimental Medicine</i> , 1982, 156, 1165-1176.	8.5	132
17	Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. <i>Journal of Immunology</i> , 1989, 143, 2677-83.	0.8	128
18	Group A Streptococcal Pharyngitis Serotype Surveillance in North America, 2000-2002. <i>Clinical Infectious Diseases</i> , 2004, 39, 325-332.	5.8	115

#	ARTICLE	IF	CITATIONS
19	Sequence of myosin-crossreactive epitopes of streptococcal M protein.. Journal of Experimental Medicine, 1986, 164, 1785-1790.	8.5	113
20	Status of research and development of vaccines for Streptococcus pyogenes. Vaccine, 2016, 34, 2953-2958.	3.8	113
21	Serum opacity factor is a major fibronectin-binding protein and a virulence determinant of M type 2 Streptococcus pyogenes. Molecular Microbiology, 1999, 32, 89-98.	2.5	109
22	Temporal Changes in Streptococcal M Protein Types and the Near-Disappearance of Acute Rheumatic Fever in the United States. Clinical Infectious Diseases, 2006, 42, 441-447.	5.8	108
23	Differential effects of the streptococcal fibronectin-binding protein, FBP54, on adhesion of group A streptococci to human buccal cells and HEp-2 tissue culture cells. Infection and Immunity, 1996, 64, 2415-2419.	2.2	104
24	Seven-Year Surveillance of North American Pediatric Group A Streptococcal Pharyngitis Isolates. Clinical Infectious Diseases, 2009, 49, 78-84.	5.8	97
25	Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. Vaccine, 1999, 17, 193-200.	3.8	91
26	Prospects for a Group A Streptococcal Vaccine: Rationale, Feasibility, and Obstacles--Report of a National Institute of Allergy and Infectious Diseases Workshop. Clinical Infectious Diseases, 2005, 41, 1150-1156.	5.8	91
27	Relationship between Expression of the Family of M Proteins and Lipoteichoic Acid to Hydrophobicity and Biofilm Formation in Streptococcus pyogenes. PLoS ONE, 2009, 4, e4166.	2.5	88
28	Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine, 2013, 31, 1576-1581.	3.8	82
29	Group A streptococcal vaccines: Paving a path for accelerated development. Vaccine, 2013, 31, B216-B222.	3.8	79
30	Identification of a Gene within a Pathogenicity Island of Enterotoxigenic Escherichia coli H10407 Required for Maximal Secretion of the Heat-Labile Enterotoxin. Infection and Immunity, 2000, 68, 2766-2774.	2.2	77
31	Localization of protective epitopes of the amino terminus of type 5 streptococcal M protein.. Journal of Experimental Medicine, 1986, 163, 1191-1202.	8.5	76
32	Intranasal Immunization with Multivalent Group A Streptococcal Vaccines Protects Mice against Intranasal Challenge Infections. Infection and Immunity, 2004, 72, 2507-2512.	2.2	76
33	The Importance of the Group A Streptococcus Capsule in the Pathogenesis of Human Infections: A Historical Perspective. Clinical Infectious Diseases, 2008, 46, 1038-1045.	5.8	75
34	Lipoteichoic acid and M protein: dual adhesins of group A streptococci. Microbial Pathogenesis, 1992, 12, 199-208.	2.9	74
35	Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein.. Journal of Experimental Medicine, 1983, 158, 1727-1732.	8.5	73
36	Common protective antigens of group A streptococcal M proteins masked by fibrinogen.. Journal of Experimental Medicine, 1984, 159, 1201-1212.	8.5	73

#	ARTICLE	IF	CITATIONS
37	Recombinant, octavalent group A streptococcal M protein vaccine. <i>Vaccine</i> , 1996, 14, 944-948.	3.8	71
38	Anti-phagocytic mechanisms of <i>Streptococcus pyogenes</i> : binding of fibrinogen to M-related protein. <i>Molecular Microbiology</i> , 2006, 59, 936-947.	2.5	71
39	Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. <i>Journal of Immunology</i> , 1992, 148, 888-93.	0.8	69
40	The Reemergence of Serious Group A Streptococcal Infections and Acute Rheumatic Fever. <i>American Journal of the Medical Sciences</i> , 1996, 311, 41-54.	1.1	66
41	Analysis of the role of M24 protein in group A streptococcal adhesion and colonization by use of omega-interposon mutagenesis. <i>Infection and Immunity</i> , 1994, 62, 4868-4873.	2.2	63
42	New protective antigen of group A streptococci. <i>Journal of Clinical Investigation</i> , 1999, 103, 1261-1268.	8.2	58
43	Comparison of the leader sequences of four group A streptococcal M protein genes. <i>Nucleic Acids Research</i> , 1988, 16, 4667-4677.	14.5	57
44	Serum Opacity Factor (SOF) of <i>Streptococcus pyogenes</i> Evokes Antibodies That Opsonize Homologous and Heterologous SOF-Positive Serotypes of Group A Streptococci. <i>Infection and Immunity</i> , 2003, 71, 5097-5103.	2.2	56
45	Update on group A streptococcal vaccine development. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 244-250.	3.1	56
46	Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study. <i>Vaccine</i> , 2020, 38, 1384-1392.	3.8	53
47	Protective immunogenicity and T lymphocyte specificity of a trivalent hybrid peptide containing NH2-terminal sequences of types 5, 6, and 24 M proteins synthesized in tandem.. <i>Journal of Experimental Medicine</i> , 1987, 166, 647-656.	8.5	52
48	Protective and heart-crossreactive epitopes located within the NH2 terminus of type 19 streptococcal M protein.. <i>Journal of Experimental Medicine</i> , 1988, 167, 1849-1859.	8.5	51
49	Opsonic Antibodies to the Surface M Protein of Group A Streptococci in Pooled Normal Immunoglobulins (IVIG): Potential Impact on the Clinical Efficacy of IVIG Therapy for Severe Invasive Group A Streptococcal Infections. <i>Infection and Immunity</i> , 1998, 66, 2279-2283.	2.2	51
50	Epitopes of group A streptococcal M protein shared with antigens of articular cartilage and synovium. <i>Journal of Immunology</i> , 1991, 146, 3132-7.	0.8	50
51	Passive Protection of Mice against Group A Streptococcal Pharyngeal Infection by Lipoteichoic Acid. <i>Journal of Infectious Diseases</i> , 1994, 169, 319-323.	4.0	49
52	Multivalent Group A Streptococcal Vaccine Elicits Bactericidal Antibodies against Variant M Subtypes. <i>Vaccine Journal</i> , 2005, 12, 833-836.	3.1	48
53	Recombinant tetravalent group A streptococcal M protein vaccine. <i>Journal of Immunology</i> , 1993, 151, 2188-94.	0.8	48
54	Hybridoma antibodies against protective and nonprotective antigenic determinants of a structurally defined polypeptide fragment of streptococcal M protein.. <i>Journal of Experimental Medicine</i> , 1982, 155, 1010-1018.	8.5	47

#	ARTICLE	IF	CITATIONS
55	Prospective Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal Acquisition of Group A Streptococci. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, 187-196.	1.3	47
56	Sequence of protective epitopes of streptococcal M proteins shared with cardiac sarcolemmal membranes. <i>Journal of Immunology</i> , 1987, 139, 1285-90.	0.8	47
57	Current Status of Group A Streptococcal Vaccine Development. <i>Advances in Experimental Medicine and Biology</i> , 2008, 609, 53-63.	1.6	46
58	Repeating covalent structure and protective immunogenicity of native and synthetic polypeptide fragments of type 24 streptococcal M protein. Mapping of protective and nonprotective epitopes with monoclonal antibodies.. <i>Journal of Biological Chemistry</i> , 1983, 258, 13250-13257.	3.4	46
59	Protective and autoimmune epitopes of streptococcal M proteins. <i>Vaccine</i> , 1988, 6, 192-196.	3.8	45
60	Intranasal Immunization with Recombinant Group A Streptococcal M Protein Fragment Fused to the B Subunit of Escherichia coli Labile Toxin Protects Mice against Systemic Challenge Infections. <i>Journal of Infectious Diseases</i> , 1995, 171, 1038-1041.	4.0	45
61	Immune Cross-Opsonization Withinemm Clusters Following Group AStreptococcus Skin Infection: Broadening the Scope of Type-Specific Immunity. <i>Clinical Infectious Diseases</i> , 2017, 65, 1523-1531.	5.8	45
62	Heterogeneity of type-specific and cross-reactive antigenic determinants within a single M protein of group A streptococci.. <i>Journal of Experimental Medicine</i> , 1980, 151, 1026-1038.	8.5	43
63	The Reemergence of Serious Group A Streptococcal Infections and Acute Rheumatic Fever. <i>American Journal of the Medical Sciences</i> , 1996, 311, 41-54.	1.1	42
64	Structure-based design of broadly protective group a streptococcal M protein-based vaccines. <i>Vaccine</i> , 2017, 35, 19-26.	3.8	41
65	Repeating covalent structure and protective immunogenicity of native and synthetic polypeptide fragments of type 24 streptococcal M protein. Mapping of protective and nonprotective epitopes with monoclonal antibodies. <i>Journal of Biological Chemistry</i> , 1983, 258, 13250-7.	3.4	41
66	Added Value of the emm-Cluster Typing System to Analyze Group A Streptococcus Epidemiology in High-Income Settings. <i>Clinical Infectious Diseases</i> , 2014, 59, 1651-1652.	5.8	40
67	Human cytotoxic T lymphocytes evoked by group A streptococcal M proteins.. <i>Journal of Experimental Medicine</i> , 1987, 166, 1825-1835.	8.5	39
68	A 28-kilodalton fibronectin-binding protein of group a streptococci. <i>Current Microbiology</i> , 1992, 25, 245-250.	2.2	39
69	Inactivation of DltA Modulates Virulence Factor Expression in Streptococcus pyogenes. <i>PLoS ONE</i> , 2009, 4, e5366.	2.5	39
70	Progress Toward a Global Group A Streptococcal Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 180-182.	2.0	38
71	Conversion of M serotype 24 of Streptococcus pyogenes to M serotypes 5 and 18: effect on resistance to phagocytosis and adhesion to host cells. <i>Infection and Immunity</i> , 1997, 65, 2472-2474.	2.2	37
72	Attachment of Streptococcus pyogenes to Mammalian Cells. <i>Clinical Infectious Diseases</i> , 1983, 5, S670-S677.	5.8	36

#	ARTICLE	IF	CITATIONS
73	Antibodies against a Synthetic Peptide of SagA Neutralize the Cytolytic Activity of Streptolysin S from Group A Streptococci. <i>Infection and Immunity</i> , 2002, 70, 2166-2170.	2.2	36
74	Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes. <i>Vaccine</i> , 2010, 28, 5017-5022.	3.8	36
75	Monoclonal antibody to human renal glomeruli cross-reacts with streptococcal M protein. <i>Infection and Immunity</i> , 1987, 55, 2416-2419.	2.2	36
76	Blastogenic responses of human lymphocytes to structurally defined polypeptide fragments of streptococcal M protein. <i>Journal of Immunology</i> , 1981, 126, 1499-505.	0.8	36
77	Group A Streptococcal emm Type Prevalence Among Symptomatic Children in Cape Town and Potential Vaccine Coverage. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 208-210.	2.0	33
78	Sequence and type-specific immunogenicity of the amino-terminal region of type 1 streptococcal M protein. <i>Journal of Immunology</i> , 1987, 139, 3084-90.	0.8	33
79	Controlled human infection for vaccination against <i>Streptococcus pyogenes</i> (CHIVAS): Establishing a group A <i>Streptococcus</i> pharyngitis human infection study. <i>Vaccine</i> , 2019, 37, 3485-3494.	3.8	31
80	Progress in Group A Streptococcal Vaccine Development. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, 765-766.	2.0	30
81	The American Heart Association's Call to Action for Reducing the Global Burden of Rheumatic Heart Disease: A Policy Statement From the American Heart Association. <i>Circulation</i> , 2020, 142, e358-e368.	1.6	30
82	Spa Contributes to the Virulence of Type 18 Group A Streptococci. <i>Infection and Immunity</i> , 2001, 69, 2943-2949.	2.2	29
83	Mapping the Fibrinogen-Binding Domain of Serum Opacity Factor of Group A Streptococci. <i>Current Microbiology</i> , 2002, 44, 236-240.	2.2	29
84	A controlled human infection model of <i>Streptococcus pyogenes</i> pharyngitis (CHIVAS-M75): an observational, dose-finding study. <i>Lancet Microbe</i> , The, 2021, 2, e291-e299.	7.3	29
85	Unique and common protective epitopes among different serotypes of group A streptococcal M proteins defined with hybridoma antibodies. <i>Infection and Immunity</i> , 1984, 46, 267-269.	2.2	26
86	Protective immunity evoked by locally administered group A streptococcal vaccines in mice. <i>Journal of Immunology</i> , 1988, 141, 2767-70.	0.8	24
87	Comparison of adherence to and penetration of a human laryngeal epithelial cell line by group A streptococci of various M protein types. <i>FEMS Immunology and Medical Microbiology</i> , 1999, 23, 195-204.	2.7	23
88	GROUP A STREPTOCOCCAL VACCINES. <i>Infectious Disease Clinics of North America</i> , 1999, 13, 227-243.	5.1	23
89	Type-specific antibodies to structurally defined fragments of streptococcal M proteins in patients with acute rheumatic fever. <i>Infection and Immunity</i> , 1982, 38, 573-579.	2.2	22
90	Prevalence of group A $\beta$ -hemolytic streptococcal throat carriage and prospective pilot surveillance of streptococcal sore throat in Ugandan school children. <i>International Journal of Infectious Diseases</i> , 2020, 93, 245-251.	3.3	21

#	ARTICLE	IF	CITATIONS
91	Vaccination against the M protein of <i>Streptococcus pyogenes</i> prevents death after influenza virus: <i>S. pyogenes</i> super-infection. <i>Vaccine</i> , 2014, 32, 5241-5249.	3.8	20
92	Expression of protective and cardiac tissue cross-reactive epitopes of type 5 streptococcal M protein in <i>Escherichia coli</i> . <i>Infection and Immunity</i> , 1985, 48, 198-203.	2.2	20
93	A double-blind, randomized phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults. <i>International Congress Series</i> , 2006, 1289, 303-306.	0.2	19
94	Streptococcal Pharyngitis in Schoolchildren in Bamako, Mali. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 463-468.	2.0	19
95	Protective Immunogenicity of Group A Streptococcal M-Related Proteins. <i>Vaccine Journal</i> , 2015, 22, 344-350.	3.1	18
96	Trivalent M-related protein as a component of next generation group A streptococcal vaccines. <i>Clinical and Experimental Vaccine Research</i> , 2017, 6, 45.	2.2	18
97	The Cape Town Clinical Decision Rule for Streptococcal Pharyngitis in Children. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 250-255.	2.0	16
98	Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against <i>Streptococcus pyogenes</i> . <i>MSphere</i> , 2018, 3, .	2.9	16
99	Rationale and design of the African group A streptococcal infection registry: the AFROStrepstudy. <i>BMJ Open</i> , 2016, 6, e010248.	1.9	13
100	Systematic Review and Meta-analysis of the Prevalence of Group A Streptococcal <i>emm</i> Clusters in Africa To Inform Vaccine Development. <i>MSphere</i> , 2020, 5, .	2.9	11
101	Dynamic epidemiology of group A streptococcal serotypes. <i>Lancet, The</i> , 2002, 359, 889.	13.7	10
102	Streptococcal protective antigens (Spa): a new family of type-specific proteins of group A streptococci. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2010, 29, 51-57.	2.9	9
103	Design of Broadly Cross-Reactive M Protein-Based Group A Streptococcal Vaccines. <i>Journal of Immunology</i> , 2021, 207, 1138-1149.	0.8	9
104	A Novel Live Vector Group A Streptococcal <i>emm</i> Type 9 Vaccine Delivered Intranasally Protects Mice against Challenge Infection with <i>emm</i> Type 9 Group A Streptococci. <i>Vaccine Journal</i> , 2014, 21, 1343-1349.	3.1	8
105	One More Disguise in the Stealth Behavior of <i>Streptococcus pyogenes</i> . <i>MBio</i> , 2016, 7, .	4.1	8
106	Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides. <i>Journal of Biological Chemistry</i> , 2020, 295, 3826-3836.	3.4	8
107	Molecular Epidemiology of Noninvasive and Invasive Group A Streptococcal Infections in Cape Town. <i>MSphere</i> , 2019, 4, .	2.9	7
108	The NH <sub>2</sub> Terminal Region of <i>Streptococcus pyogenes</i> M5 Protein Confers Protection against Degradation by Proteases and Enhances Mucosal Colonization of Mice. <i>Journal of Infectious Diseases</i> , 2010, 201, 1580-1588.	4.0	6

#	ARTICLE	IF	CITATIONS
109	Group A Streptococcus Expresses a Trio of Surface Proteins Containing Protective Epitopes. <i>Vaccine Journal</i> , 2014, 21, 1421-1425.	3.1	6
110	Protective immunity induced by an intranasal multivalent vaccine comprising 10 <i>Lactococcus lactis</i> strains expressing highly prevalent M protein antigens derived from Group A <i>Streptococcus</i> . <i>Microbiology and Immunology</i> , 2018, 62, 395-404.	1.4	6
111	Age-associated differences in prevalence of group A streptococcal type-specific M antibodies in children. <i>European Journal of Pediatrics</i> , 2009, 168, 679-683.	2.7	5
112	Progress in the Development of Effective Vaccines to Prevent Selected Gram-Positive Bacterial Infections. <i>American Journal of the Medical Sciences</i> , 2010, 340, 218-225.	1.1	5
113	Clinical and microbiological response of mice to intranasal inoculation with <i>Lactococcus lactis</i> expressing Group A <i>Streptococcus</i> antigens, to be used as an anti-streptococcal vaccine. <i>Microbiology and Immunology</i> , 2018, 62, 711-719.	1.4	5
114	Group A Streptococcal Vaccines. <i>Pediatric Annals</i> , 1998, 27, 301-308.	0.8	5
115	Protective antibody against a peptide fragment of type 5 streptococcal M protein cross-reacts with human heart tissue. <i>Transactions of the Association of American Physicians</i> , 1982, 95, 286-91.	0.1	5
116	Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes. <i>Vaccine</i> , 2021, 39, 1773-1779.	3.8	4
117	Immunotherapy targeting the <i>Streptococcus pyogenes</i> M protein or streptolysin O to treat or prevent influenza A superinfection. <i>PLoS ONE</i> , 2020, 15, e0235139.	2.5	3
118	Group A Streptococcal Virulence: New Lessons. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 160-161.	1.3	2
119	Utility of Human Immune Responses to GAS Antigens as a Diagnostic Indicator for ARF: A Systematic Review. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 691646.	2.4	2
120	Five-year group A streptococcal pharyngitis serotype surveillance in North America, 2000–2005. <i>International Congress Series</i> , 2006, 1289, 30-33.	0.2	1
121	Why acute rheumatic fever has virtually disappeared in the U.S.. <i>International Congress Series</i> , 2006, 1289, 285-288.	0.2	1
122	Structure-Function Analysis of Group A Streptococcal M Proteins with Hybridoma Antibodies. , 1985, , 1-21.		1
123	Phosphorylase-cross-reactive antibodies evoked by streptococcal M protein. <i>Infection and Immunity</i> , 1990, 58, 774-778.	2.2	1
124	Southern Society for Clinical Investigation Founders' Medal Recipient's Address. <i>American Journal of the Medical Sciences</i> , 2002, 324, 61-62.	1.1	0
125	Macrolide resistance among pediatric pharyngeal Group A streptococci is high in Canada and increasing in the US. <i>International Congress Series</i> , 2006, 1289, 95-98.	0.2	0
126	Role of the Mga regulon in the resistance of M type 4 <i>Streptococcus pyogenes</i> to phagocytosis. <i>International Congress Series</i> , 2006, 1289, 195-198.	0.2	0